Andrx Can't Beat AstraZeneca's Prilosec Patent Suit

Law360, Los Angeles (August 6, 2013, 6:46 PM EDT) -- A New York federal judge on Monday refused to kill AstraZeneca's suit seeking nearly $500 million over Andrx Pharmaceuticals Inc.'s manufacture of a generic version of its indigestion drug Prilosec, saying the suit doesn't raise the possibility of an improper double recovery. 

U.S. District Judge Denise Cote denied Andrx's motion for summary judgment to bar Astra from seeking monetary damages over its allegedly infringing manufacture of generic Prilosec, or omeprazole. Judge Cote said that while another judge already entered final judgment enjoining Andrx from producing the...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.